Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
AI epigenomics platform for neurodegenerative disease detection
Prima Mente is a biotechnology company developing large-scale biological foundation models to understand and detect neurodegenerative disease. The company generates proprietary multi-omic data including whole-epigenome sequencing, and trains transformer-based models on DNA methylation patterns in cell-free DNA to…
Spider-inspired protein fibre spinning for sustainable and biocompatible materials
Spintex Engineering is a developer of bioinspired silk fibres, produced from a liquid protein feedstock using a spider-inspired self-assembly process. The technology requires no hazardous chemicals, with water as the only by-product, and is significantly more energy efficient than synthetic fibre production. Spintex's…
Virus-like particle therapeutics for chronic inflammatory skin conditions
Glen Clova Scientific is a biotechnology company developing active biologic drugs for chronic inflammatory and autoimmune disorders, with an initial focus on immuno-dermatology. Its proprietary virus-like particle platform is designed to induce targeted immune responses against self-produced proteins that drive…
Novel antibiotic-sparing therapeutics for chronic wound care
ONYA Therapeutics is a biotechnology company developing novel pharmaceutical treatments for acute and chronic wounds. The company's pipeline centres on a patented controlled-release drug delivery technology designed to manage wound exudate and reduce reliance on antibiotics, addressing antimicrobial resistance in…
DNA nanoprobes for intracellular biomarker profiling in neurodegeneration
Esya Labs is a precision biomarker company using patented DNA nanoprobes to measure ion signatures within intracellular organelles including endosomes and lysosomes. The technology enables ratiometric quantification of subcellular chemical states in living cells, with applications in early detection of…
Multimodal engineered T-cell therapies for treatment-refractory solid cancers
Alceus Bio is a biotechnology company developing next-generation engineered T-cell therapies for solid tumours. Its platform uses generative AI and synthetic biology to design therapeutic proteins that patient-derived immune cells are programmed to express and deliver in situ, targeting intracellular disease drivers…
Breath-based volatile organic compound test for multi-cancer detection
SpiraCheck is a biotechnology company developing a non-invasive breath test for the early detection of gastrointestinal cancers. Patients exhale into a collection device; the sample is analysed in the laboratory by mass spectrometry to quantify volatile organic compounds, and a patented algorithm interprets the…
Precision medicine platform matching cancer patients to optimal therapies
Pathway Bio is a precision oncology company developing a functional platform to predict treatment response in individual cancer patients. The platform combines multiomic tumour profiling, AI-driven modelling, and ex vivo microcancer technology to screen therapies against a biological avatar of the patient's own tumour…
Inorganic nanoscale immune modulators for infection, cancer and autoimmunity
Iuvantium is a biotechnology company developing therapeutics and vaccines based on inorganic nanoscale materials that modulate the immune system. The company uses tailored inorganic probes to study how the immune system responds, builds a computational model of immune behaviour, and designs programmable immune…
Engineered iPSC-derived exosomes for tissue-targeted drug delivery
Excellio Labs is a biotech developing engineered exosome platforms for targeted drug delivery. The technology exploits the inherent tissue-specificity of iPSC-derived extracellular vesicles, which are further surface-modified to create precision drug carriers capable of delivering nucleic acids, proteins, and small…
Hydrogel capsule platform for weight loss and oral drug delivery
Oxford Medical Products is developing a gastroretentive hydrogel platform with two applications. The technology is a swallowable dual-polymer capsule that expands in the stomach to suppress appetite without pharmacological intervention; a Phase 2a clinical trial is underway following positive Phase 1 results. Oxford…
Off-the-shelf cell therapies for cancer and rare diseases
Empyrean Therapeutics develops off-the-shelf cell therapies intended to make treatments for cancer and rare diseases more accessible. Its approach combines gene editing, stem cell programming and precise genetic control to engineer therapeutic cells. The company is developing cell platforms and manufacturing processes…
Small molecule remyelination therapeutics for neurological diseases
Pheno Therapeutics is a Scottish clinical-stage biotechnology company developing small molecule therapeutics that promote remyelination by boosting the function of oligodendrocytes in the central nervous system. Its lead programme PTD802, a selective GPR17 antagonist licensed from UCB, received MHRA clinical trial…
AI-driven delivery platform for siRNA therapies beyond the liver
Undecimal Bio is a biotechnology company developing targeted delivery technologies for small interfering RNA (siRNA) therapeutics beyond the liver. Its DELiveri platform combines large-scale combinatorial chemistry, functional cell-based screening and AI to identify synthetic conjugates that transport siRNA into…
Long-acting eye-drop matrix technology for chronic ocular surface disease
Healome Therapeutics is a University of Birmingham spin-out developing a proprietary eye-drop matrix technology that improves drug retention, lubrication and healing on the eye surface. Unlike conventional eye drops, which clear within minutes and often require dosing many times a day, Healome's platform behaves like…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis, type 1 diabetes and inflammatory bowel disease. The company reprograms pathogenic T cells into homeostatic, anti-inflammatory cells directly…
Rapid point-of-care bacterial diagnostics and antibiotic susceptibility testing
FluoretiQ Limited is a diagnostics company developing rapid point-of-care tools for bacterial identification and antibiotic susceptibility testing to support antimicrobial stewardship. Its platform uses functionalised nanoparticles and machine learning to identify and quantify bacterial pathogens from clinical samples…
Targeted antibacterial gel for gum disease
Sysora Health develops a targeted antibacterial gel for periodontitis, a severe form of gum disease. Its approach aims to eliminate Porphyromonas gingivalis, a bacterium implicated in gum inflammation, while preserving beneficial microorganisms in the oral microbiome. The company is investigating selective bacterial…
AI-driven microRNA biomarker diagnostics for early veterinary disease detection
MI:RNA Diagnostics is a UK-based developer of a diagnostic platform combining microRNA biomarker panels with a proprietary artificial intelligence model to detect early-stage disease in animals. The company's flagship application targets cardiac disease in cats and dogs, with further research into Johne's disease…
Oral microbiome therapeutics for gastrointestinal and hepatic disease
EnteroBiotix is a clinical-stage biopharmaceutical company developing orally delivered, full-spectrum microbiome therapeutics for diseases linked to gut microbiome disruption. Its lead asset EBX-102-02 demonstrated clinically meaningful improvements in irritable bowel syndrome in Phase 2a trials, with a Phase 2b study…